1401-Targeting STAT3 to Overcome Chemoresistance in AML
This research identifies lipid metabolism reprogramming as a critical driver of chemotherapy resistance in acute myeloid leukemia (AML). The study reveals that resistant leukemia cells survive by upregulating STAT3 signaling, which transcriptionally activates key regulators of lipid synthesis and oxidation, namely SREBP1 and CPT2. To combat this, researchers developed W1307, a highly selective STAT3 inhibitor that disrupts lipid homeostasis and induces lipotoxicity by causing an accumulation of toxic metabolic intermediates and oxidative stress. Experimental results demonstrate that W1307…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.